HRT and GLP-1: Combining Menopause Hormones and Weight Loss
Perimenopause is when weight and hormones collide. Many women arrive at a GLP-1 already asking their gynecologist about hot flashes, sleep, and mood, and they want to know a fair question: can I do both? Can I be on menopause hormone therapy and a GLP-1 medication at the same time?
This article answers that. It is educational, not a prescription pitch. Transformation Health is an independent GLP-1 guide and does not prescribe hormone therapy or GLP-1 medications, so the goal here is to help you understand how the two fit together so you can have a better conversation with the providers who manage each one.
Two different problems, two different tools
The clearest way to think about this is that hormone therapy and a GLP-1 are aimed at different parts of the same difficult season.
Menopause hormone therapy, often called HRT or MHT, replaces estrogen, usually with progesterone if you have a uterus. It is prescribed to treat menopausal symptoms such as hot flashes, night sweats, sleep disruption, and genitourinary changes, and it has been shown to prevent bone loss and fracture.[1] It is not a weight loss treatment.
A GLP-1 medication works on appetite and the food noise that so many women describe intensifying in midlife. It supports weight management as part of a broader plan. It does nothing for hot flashes.
Treats menopausal symptoms
Aimed at hot flashes, night sweats, sleep, mood, and genitourinary changes, with a role in bone health. Prescribed by your gynecologist or menopause provider. Not a weight loss treatment.
Supports weight management
Works on appetite and food noise as part of a weight management plan. Prescribed if a provider determines it is appropriate. Does nothing for menopausal symptoms.
The reason they come up together is that perimenopause changes both things at once. Research on the menopause transition links the hormonal change to more total and abdominal fat: in the SWAN study, the rate of fat gain doubled and lean mass began to decline at the start of the transition, and a 4-year study found visceral fat rose in women who reached menopause.[2][3][4] Many women also describe stronger appetite and food noise in this stage. So a woman in this stage may genuinely need help with symptoms on one side and with weight on the other. That is two problems, and it is reasonable to address both.
Can you use them together?
For many women, yes, and they are frequently used together. There is no blanket rule that says you cannot be on hormone therapy and a GLP-1 at the same time, and no automatic drug interaction that rules it out for everyone.
The real work is coordination. Because hormone therapy and a GLP-1 are usually prescribed by different providers, the single most important thing you can do is make sure each one knows what the other has prescribed. That is not a formality. A complete medication list is how your providers catch anything specific to your health history, because “generally compatible” is not the same as “right for you.”
The oral versus transdermal question
There is one practical detail worth understanding, and it mirrors what is already known about GLP-1 medications and oral birth control.
The Wegovy (semaglutide) and Zepbound (tirzepatide) labels say these medications delay gastric emptying and may affect the absorption of other oral medications.[7][8] Neither label addresses menopause hormone therapy specifically. For birth control pills, the labels differ: the Zepbound label advises switching to a non-oral method, or adding a barrier method for 4 weeks after starting and after each dose increase, while the Wegovy label lists no clinically significant change in the pill hormones it tested.[7][8] That is covered in GLP-1 and Birth Control. The Wegovy tablet label also says to wait at least 30 minutes after the tablet before taking other oral medications.[7] If you take estrogen as a pill, it is worth asking your prescriber whether timing or monitoring matters for you.
Transdermal forms of estrogen, such as patches and gels, are absorbed through the skin rather than the digestive tract, so this absorption question does not apply to them in the same way. Route also matters for other reasons: in a large UK study, oral hormone therapy was linked to a higher risk of blood clots, while transdermal preparations were not.[5] None of this is a decision to make on your own, but it is a useful thing to raise.
What hormone therapy will and will not do for weight
It is worth being honest here, because the internet is not. Hormone therapy is not a weight loss drug, and it should not be started with weight loss as the goal.
What the research suggests is more subtle: a review by an International Menopause Society writing group concluded that estrogen therapy may partly prevent the menopause-related shift toward abdominal fat.[2] That is not the same as causing meaningful weight loss, and expecting it to melt away pounds sets you up for disappointment. In this pairing, the GLP-1 is the tool aimed at weight, and hormone therapy is aimed at symptoms. Keeping that distinction straight protects you from both false hope and the wrong prescription.
Muscle and bone deserve extra attention
Menopause and weight loss share a hidden risk: both can work against your bones and muscle. Estrogen decline accelerates bone loss, and any significant weight loss can reduce bone density and lean mass if nothing is done to protect them.
This is where the boring fundamentals earn their keep. Adequate protein, resistance training, and the calcium and vitamin D your labs indicate you need all become more important during this stage, not less. Hormone therapy supports bone health for women who are on it, and resistance training protects muscle for everyone. If you are losing weight through menopause, treat bone and muscle as an active priority, not an afterthought. Start with Resistance Training on GLP-1 and Perimenopause Nutrition on GLP-1.
Risks and decisions belong to your prescriber
Hormone therapy has a real risk and benefit profile that is individual to you. For women who are under 60 or within 10 years of menopause onset and have no contraindications, the 2022 hormone therapy position statement of The Menopause Society (then called The North American Menopause Society) describes the benefit-risk ratio as favorable for bothersome hot flashes and preventing bone loss; for women who start later or are over 60, it appears less favorable.[1] Oral estrogen has been linked to a higher clot risk than transdermal,[5] and your personal and family history matters. These are exactly the decisions a menopause-informed provider is there to make with you.
One accuracy note that fits the theme of this whole section: compounded “bioidentical” hormone products are not FDA-approved, and the American College of Obstetricians and Gynecologists says compounded bioidentical hormone therapy should not be prescribed routinely when FDA-approved formulations exist.[6] If someone offers you a custom hormone blend framed as safer or more natural, treat that claim with the same skepticism you would apply to any supplement.
The bottom line
Menopause hormone therapy and a GLP-1 are not rivals, and for many women they are not mutually exclusive. They solve different problems: one treats menopausal symptoms, the other supports weight management. They can often be used together with provider coordination. The main practical wrinkle is the absorption question with oral hormones, and neither should be asked to do the other’s job.
Keep each provider fully informed, protect your bone and muscle deliberately, and let the clinicians who manage each therapy make the calls that are theirs to make.
What to read next
For eating through this stage, read Perimenopause Nutrition on GLP-1. For the absorption detail with oral hormones, GLP-1 and Birth Control explains the same mechanism. And for the full section on what to combine with a GLP-1, see the Supplements and Interactions With GLP-1 overview.
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation, and never start, stop, or change a medication, including hormone therapy, without guidance from your prescriber. Transformation Health is an independent GLP-1 guide. It does not provide medical care, prescribe, compound, or sell medication, including hormone therapy. GLP-1 medications are not approved to treat menopause symptoms and are not hormone therapy. A licensed provider decides whether a prescription is appropriate. Compounded bioidentical hormone products are not FDA-approved. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as brand-name products such as Wegovy or Zepbound. The FDA does not review compounded medications for safety, effectiveness, or quality, and they may differ in formulation, purity, and potency. Always tell every provider the full list of medications you take. Results vary. Wegovy is a trademark of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies. Transformation Health does not accept payment from providers. How we make money.
Citations
[1] The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. “The 2022 hormone therapy position statement of The North American Menopause Society.” Menopause. 2022;29(7):767-794. PMID: 35797481.
[2] Davis SR, Castelo-Branco C, Chedraui P, et al. “Understanding weight gain at menopause.” Climacteric. 2012;15(5):419-429. PMID: 22978257.
[3] Greendale GA, Sternfeld B, Huang M, et al. “Changes in body composition and weight during the menopause transition.” JCI Insight. 2019;4(5):e124865. PMID: 30843880.
[4] Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. “Increased visceral fat and decreased energy expenditure during the menopausal transition.” International Journal of Obesity. 2008;32(6):949-958. PMID: 18332882.
[5] Vinogradova Y, Coupland C, Hippisley-Cox J. “Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.” BMJ. 2019;364:k4810. PMID: 30626577.
[6] American College of Obstetricians and Gynecologists’ Committee on Clinical Consensus-Gynecology. “Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6.” Obstetrics and Gynecology. 2023;142(5):1266-1273. PMID: 37856860.
[7] Novo Nordisk. Wegovy (semaglutide) prescribing information. US Food and Drug Administration. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf (Section 2.1: wait at least 30 minutes after the tablet before other oral medications; section 7.2: delayed gastric emptying and oral medications; section 12.3: no clinically significant change in ethinyl estradiol or levonorgestrel.)
[8] Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. US Food and Drug Administration. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf (Section 7.2: delayed gastric emptying, oral medications, and oral hormonal contraceptive instructions; section 8.3.)